Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Replimune Group Inc    REPL

REPLIMUNE GROUP INC

(REPL)
 SummaryQuotesChartsNewsCompany 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
04/12/2019 04/15/2019 04/16/2019 04/17/2019 04/18/2019 Date
15.11(c) 13.03(c) 12.51(c) 12.71(c) 14.5(c) Last
40 087 63 222 60 975 108 340 25 976 Volume
-1.24% -13.77% -3.99% +1.60% +14.08% Change
More quotes
Company
Replimune Group, Inc. is a clinical-stage biotechnology company. The Company is engaged in the field of oncolytic immunotherapy to treat the cancer patients. The Company applies its Immulytic platform to design and develop product candidates that are intended to maximally activate the immune system... 
More about the company
Latest news on REPLIMUNE GROUP INC
04/01REPLIMUNE : Announces Presentation at the American Association for Cancer Resear..
AQ
02/16REPLIMUNE : Reports Financial Results for the Third Fiscal Quarter, Ended Decemb..
AQ
02/14REPLIMUNE GROUP, INC. : Results of Operations and Financial Condition, Financial..
AQ
02/14REPLIMUNE : 2015 Enterprise Management Incentive Share Option Plan
AQ
02/14Replimune Reports Financial Results for the Third Fiscal Quarter, Ended Decem..
GL
02/07Replimune to Present at Two Upcoming Investor Conferences
GL
01/03REPLIMUNE : Highlights Company Progress and Expected 2019 Milestones Ahead of Pr..
AQ
2018Replimune to Present at the 37th Annual J.P.Morgan Healthcare Conference
GL
2018Replimune to Present at the BMO Capital Markets 2018 Prescriptions for Succes..
GL
2018REPLIMUNE GROUP, INC. : Results of Operations and Financial Condition, Financial..
AQ
More news
Sector news : Biotechnology & Medical Research - NEC
04/16GILEAD SCIENCES : Insitro to Collaborate on Nonalcoholic Steatohepatitis
DJ
04/15PATRICK THOMAS : Novartis Files Application for Macular Degeneration Treatment
DJ
04/12GILEAD SCIENCES : Novo Nordisk Plan NASH Collaboration
DJ
04/08GSK wins U.S. nod for two-drug HIV combination
RE
04/08Sanofi, Alnylam Complete Research Phase of Rare Disease Alliance
DJ
More sector news : Biotechnology & Medical Research - NEC
Chart REPLIMUNE GROUP INC
Duration : Period :
Replimune Group Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REPLIMUNE GROUP INC
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Managers
NameTitle
Robert Coffin President, Chief Executive Officer & Director
Philip Astley-Sparke Executive Chairman, Secretary & Treasurer
Colin Love Chief Operating Officer
Howard Kaufman Chief Medical Officer
Jason P. Rhodes Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
REPLIMUNE GROUP INC45.00%459
IQVIA HOLDINGS INC14.50%26 285
CELLTRION, INC.--.--%22 914
LONZA GROUP16.76%21 810
INCYTE CORPORATION16.31%15 847
EXACT SCIENCES CORPORATION46.13%11 596